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A Novel Cause of Chronic Viral
Meningoencephalitis: Cache Valley Virus
Michael R. Wilson, MD, MAS,1,2 Dan Suan, MBBS, PhD,3
Andrew Duggins, MBBS, PhD,4 Ryan D. Schubert, MD,1,2 Lillian M. Khan, BS,5
Hannah A. Sample, BS,5 Kelsey C. Zorn, MHS,5
Aline Rodrigues Hoffman, DVM, PhD,6 Anna Blick, BS,6
Meena Shingde, FRCPA,7 and Joseph L. DeRisi, PhD5,8
Objective: Immunodeficient patients are particularly vulnerable to neuroinvasive infections that can be challenging to
diagnose. Metagenomic next generation sequencing can identify unusual or novel microbes and is therefore well
suited for investigating the etiology of chronic meningoencephalitis in immunodeficient patients.
Methods: We present the case of a 34-year-old man with X-linked agammaglobulinemia from Australia suffering
from 3 years of meningoencephalitis that defied an etiologic diagnosis despite extensive conventional testing, includ-
ing a brain biopsy. Metagenomic next generation sequencing of his cerebrospinal fluid and brain biopsy tissue was
performed to identify a causative pathogen.
Results: Sequences aligning to multiple Cache Valley virus genes were identified via metagenomic next generation
sequencing. Reverse transcription polymerase chain reaction and immunohistochemistry subsequently confirmed the
presence of Cache Valley virus in the brain biopsy tissue.
Interpretation: Cache Valley virus, a mosquito-borne orthobunyavirus, has only been identified in 3 immunocompe-
tent North American patients with acute neuroinvasive disease. The reported severity ranges from a self-limiting
meningitis to a rapidly fatal meningoencephalitis with multiorgan failure. The virus has never been known to cause a
chronic systemic or neurologic infection in humans. Cache Valley virus has also never previously been detected on
the Australian continent. Our research subject traveled to North and South Carolina and Michigan in the weeks prior
to the onset of his illness. This report demonstrates that metagenomic next generation sequencing allows for unbi-
ased pathogen identification, the early detection of emerging viruses as they spread to new locales, and the discov-
ery of novel disease phenotypes.
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Outbreaks of emerging and reemerging pathogenshave stimulated international discussion about the
most efficient means for improving early detection so
that public and private resources can be mobilized
quickly and efficiently to limit widespread transmission
and treat affected patients. There is a growing consensus
that an optimal surveillance regimen will (1) incorporate
an unbiased approach to pathogen identification and (2)
focus surveillance efforts on groups of people at high risk
for unusual infections (eg, immunodeficient patients and
people with relevant exposures).1–3 An unbiased approach
to pathogen identification is important because tradi-
tional candidate-based diagnostic tests essentially fail to
identify novel and unusual pathogens, usually due to per-
ceived rarity or exclusion from clinical consideration
based on established geographical distribution. Global
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surveillance efforts need to be streamlined, because it is
both time-consuming and costly for physicians to order
many pathogen-specific tests for geographically and clini-
cally novel organisms. Finally, in the modern era, when
international travel has become so commonplace, the
need for improved pathogen detection has become clear.
Here, we report the effective deployment of meta-
genomic next generation sequencing (mNGS) to diag-
nose Cache Valley virus (CVV), a mosquito-borne
orthobunyavirus,4 in an Australian patient with a primary
immunodeficiency suffering from chronic meningoen-
cephalitis. This case demonstrates the power of mNGS
to identify the possible movement of an emerging,
mosquito-borne virus to a new continent. Only previ-
ously associated with acute neuroinvasive disease, this
report also extends the phenotype of CVV infection in
humans.5–7
Patient and Methods
Case
The patient is a 34-year-old man from Australia with a
history of hypochondroplasia and X-linked agammaglob-
ulinemia (confirmed germline mutations in fibroblast
growth factor receptor 3 [FGFR3] and Bruton tyrosine
kinase [BTK], respectively). The antibody deficiency was
diagnosed in infancy, and the patient commenced life-
long intravenous immunoglobulin (IVIg) therapy. The
patient suffered from chronic sinusitis despite IVIg ther-
apy and was treated with clarithromycin prophylaxis.
Despite mild developmental delay and associated learning
difficulties, he completed school and vocational training
and went on to full-time employment as a retail store
manager.
In 2013, the patient traveled to the United States
on 3 occasions. The first trip was to Raleigh, North
Carolina in the spring. The second visit, in the summer
3 months later, started in Raleigh, but also included a
trip to Charleston, South Carolina, where the patient
participated in tubing along the local river. It was during
this nearly month-long trip that the patient complained
of a mosquito bite to his traveling companion. Two
weeks later, he traveled to East Lansing, Michigan. Upon
returning home to Australia 3 weeks later, the patient fell
ill within 2 days, with his parents reporting fatigue,
anorexia, and lethargy. Six days later, the patient suffered
an acute encephalitic illness characterized by fevers to
39 8C, confusion, and postictal drowsiness following 2
generalized tonic–clonic seizures. The patient was intu-
bated and transferred to the intensive care unit. Blood
tests revealed lymphocytosis (23.33 109/l, normal range
[NR]5 1.0–3.03 109/l) and a C-reactive protein level of
17.9mg/l (NR 5mg/l). Cerebrospinal fluid (CSF)
studies revealed normal concentrations of protein
(32mg/dl) and glucose (77mg/dl), with 873 106/l white
blood cells (11% neutrophils, 38% lymphocytes, 51%
monocytes) and 193 106/l red blood cells. Magnetic res-
onance imaging (MRI) of the brain revealed increased
T2 signal and restricted diffusion through the right for-
nix, extending into the right hippocampus and amygdala
(Fig 1A, B) with interval development of contrast
enhancement in the same brain structures 2 weeks later
(Fig 1C, D). Microbiological tests, including culture and
polymerase chain reaction (PCR) for candidate patho-
gens, failed to identify an organism (Tables 1 and 2).
The patient was treated empirically with acyclovir, ceftri-
axone, benzylpenicillin, and vancomycin. Vancomycin
and benzylpenicillin were discontinued due to the devel-
opment of a rash on the patient’s hip, and azithromycin
was started due to left-sided consolidation observed on
his chest x-ray. The patient completed 10 days of antimi-
crobial therapy with clinical improvement, and his sei-
zure disorder was controlled with levetiracetam and
sodium valproate. He was discharged from the hospital,
but was readmitted 4 days later with hypersomnolence
and a fluctuating level of consciousness. His antiepileptic
medications were adjusted, and he was discharged home
again. The patient made a partial recovery over the next
2 months but had new short-term memory loss. He was
ultimately able to return to work in a reduced capacity.
Over the next 2 years, the patient remained seizure free.
He utilized compensatory coping strategies at work due
to the significant short-term memory deficit, but he was
otherwise independent with activities of daily living at
home with his parents. There were reports of anxiety and
fatigue, but no specific diagnoses were made.
In the spring of 2016, the patient presented for
reevaluation. His parents reported 6 months of progres-
sive memory decline, slowing of speech, mood distur-
bance (predominantly anxiety), and intermittent tremors.
He was no longer able to work due to his encephalopa-
thy and needed assistance with activities of daily living.
Neurologic examination revealed that language was fluent
but monotonous. His Montreal Cognitive Assessment
score was 7/30 with severe impairment in visuospatial
and executive function, attention, abstraction, and
delayed recall.8 He could not perform the Luria maneu-
ver and was unable to mimic simple hand gestures. He
had a fine, jerky, postural tremor with his arms out-
stretched. He had diffuse muscle rigidity with 6 beats of
ankle clonus bilaterally. He could stand independently
but had a broad-based gait with reduced stride length,
stooped posture, and en bloc turning. A follow-up brain
MRI demonstrated interval development of diffuse cere-
bral atrophy with ex vacuo hydrocephalus and additional
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focal atrophy of the right medial temporal lobe (Fig 2C
and D). An MRI of the spinal cord was unremarkable.
Repeat CSF examination was unremarkable (Table 2)
and showed a normal opening pressure. Normal pres-
sure hydrocephalus was excluded by large volume CSF
extraction (30 ml) and comparative neuropsychological
testing.
A brain biopsy of the right frontal lobe revealed
features of meningoencephalitis, with inflamed fibrous
leptomeninges, scattered microglial nodules, and a peri-
vascular as well as interstitial lymphocytic infiltrate in
the cortex (Fig 3). The white matter also contained a
few microglial nodules and small number of perivascu-
lar lymphocytes (not shown). The perivascular and
interstitial lymphocytic infiltrate was composed pre-
dominantly of CD81 T lymphocytes. No viral cyto-
pathic changes were seen. Conventional CSF and brain
biopsy studies failed to identify a causative organism
(Table 2).
Sequencing Library Preparation
A 250 ll sample of CSF and a <50mg piece of surplus
brain biopsy tissue were collected in RNase/DNase-free
Lobind tubes (Sigma-Aldrich, St Louis, MO) and snap
frozen in liquid nitrogen. The samples were submitted
for unbiased mNGS under a research protocol (#13-
12236) for the identification of potential pathogens
approved by the institutional review board of the Univer-
sity of California, San Francisco (UCSF). A common
issue in metagenomic sequencing is that essentially all
reagents used during the library preparation process con-
tain some extraneous nucleic acid, including material
commonly present in laboratory reagents.9,10 The process
of acquiring a human sample can also introduce
unwanted nucleic acid from skin or environmental con-
tamination. To control for irrelevant sequences, an unre-
lated, uninfected human CSF sample ("control") was
prepared in parallel and sequenced on the same run in
addition to a water control. Samples were processed for
FIGURE 1: Neuroimaging from acute presentation. (A) Coronal T2-weighted/fluid-attenuated inversion recovery brain magnetic
resonance imaging (MRI) demonstrating T2 hyperintensity in the right hippocampus and amygdala (arrow). (B) Axial diffusion-
weighted imaging brain MRI demonstrating restricted diffusion in the right hippocampus and amygdala (arrow). (C, D) Sagittal
(C) and coronal (D) T1-weighted postcontrast brain MRI demonstrating contrast enhancement 2 weeks after the acute presen-
tation (arrows).
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mNGS analysis as previously described.11–13 Briefly, total
RNA was extracted. The sequencing library was prepared
with New England Biolabs’ (NEB; Ipswich, MA)
NEBNext RNA First Strand Synthesis Module (E7525)
and NEBNext Ultra Directional RNA Second Strand
Synthesis Module (E7550) to generate double-stranded
TABLE 1. Peripheral Clinical Laboratory Results
Test Site Initial Presentation, 2013 Follow-Up Evaluation, 2016
C-reactive protein Blood 17.9mg/l (5.0) <5 (5.0)
Immunoglobulin A Blood <0.07g/l (0.70–3.12)
Immunoglobulin G Blood 8.24g/l (6.39–15.60) 11.8 (6.6–15.6)
Immunoglobulin M Blood <0.20g/l (0.50–3.00)
Legionella Ag Urine Negative
Pneumococcal Ag Urine Negative
Respiratory multiplex DNA/RNA Nasal swab Enterovirus detected
Bacterial culture Blood 3 cultures: negative 5 cultures: negative
Bacterial culture Sputum Negative Beta lactamase positive,
Haemophilus influenzae
Bacterial culture Nasal swab Negative
Fungal culture Blood Negative
Chlamydia CFT Blood Negative
Legionella pneumophila (1–8) IFA titer Blood <128
Legionella longbeachae IFA titer Blood <128
Lyme EIA Blood Not detected
Lyme borrelia Ab Blood Negative
Mycoplasma pneumoniae IgM Blood Negative
AST Blood 41U/l (5–55) 18U/l (40)
ALT Blood 52U/l (5–55) 20U/l (40)
Alkaline phosphatase Blood 114IU/l (30–130) 114IU/l (30–110)
Protein Blood 64g/l (62–80) 78g/l (60–80)
GGT Blood 52U/l (60) 13U/l (50)
WBC Blood 23.33 109/l (4.0–10.0) 5.93 109/l (3.7–9.5)
Neutrophils Blood 12.83 109/l (2.0–7.0) 2.83 109/l (2.0–8.0)
Lymphocytes Blood 8.63 109/l (1.0–3.0) 2.03 109/l (1.0–4.0)
Monocytes Blood 0.93 109/l (0.2–1.0) 1.03 109/l (0.2–1.0)
Eosinophils Blood 0 (0–0.5) 0.13 109/l (0.0–0.5)
Reactive lymphocytes Blood Present
Band forms Blood 0.93 109/l
Hemoglobin Blood 152g/l (130–170) 147g/l (130–180)
Platelets Blood 4273 109/l (150–450) 3013 109/l (140–400)
Ab5 antibody; Ag5 antigen; ALT5alanine aminotransferase; AST5aspartate aminotransferase; CFT5 complement fixation test; EIA5 enzyme-linked
immunosorbent assay; GGT5 gamma-glutamyl transferase; IFA5 indirect fluorescent antibody; IgM5 immunoglobulin M; WBC5white blood cell count.
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complementary DNA (cDNA). The cDNA was con-
verted to Illumina (San Diego, CA) libraries using the
NEBNext Ultra II DNA library preparation kit (E7645)
according to the manufacturer’s recommendation and
amplified with 11 PCR cycles. The libraries were sub-
jected to an additional step to selectively deplete library
amplicons whose sequences corresponded to the human
mitochondrial genome. This was accomplished via Deple-
tion of Abundant Sequences by Hybridization (DASH), a
novel molecular technique using the CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats)-associ-
ated nuclease Cas9 in vitro.11,13 The pooled library was
size-selected using Ampure beads, and concentration was
determined using a Kapa Universal quantitative PCR kit
(Kapa Biosystems, Woburn, MA). Samples were sequenced
on an Illumina HiSeq 4000 instrument using 140/140
base pair paired-end sequencing.
Bioinformatics
Sequences were analyzed using a rapid computational
pipeline developed by the DeRisi Laboratory to classify
mNGS reads and identify potential pathogens by com-
parison to the entire National Center for Biotechnology
Information (NCBI) nucleotide (nt) reference database,
which has previously been described in detail.11,13 Briefly,
all paired-end reads were aligned to the human reference
genome 38 (hg38) and the Pan troglodytes genome (pan-
Tro4; 2011, University of California, Santa Cruz).14
Unaligned (ie, nonhuman) reads were quality filtered
using PriceSeqFilter.15 Quality filtered reads were then
compressed by cd-hit-dup (v4.6.1), and low-complexity
reads were removed via the Lempel-Ziv-Welch algo-
rithm.16,17 Next, human removal was repeated using
Bowtie2 (v2.2.4) with the same hg38 and PanTro4 refer-
ence genomes as described above.18 GSNAPL (v2015-12-
31)19 was used to align the remaining nonhuman read
pairs to the NCBI nt database and preprocessed to
remove known repetitive sequences with RepeatMasker
(vOpen-4.0; www.repeatmasker.org). The same reads
were also aligned to the NCBI nonredundant protein
(nr) database using the Rapsearch2 algorithm.20 The
resulting sequence hits identified at both the nt and
FIGURE 2: Neuroimaging at 3-year follow-up. (A, B) Axial T1-weighted brain magnetic resonance imaging (MRI) at the acute
presentation (A) and at 3-year follow-up (B) with interval development of severe, diffuse cerebral atrophy, ex vacuo hydroceph-
alus, and focal atrophy of the right hippocampus (arrow). (C, D) Sagittal T1-weighted brain MRIs at the acute presentation (C)
and at 3-year follow-up (D) with interval development of severe, diffuse cerebral atrophy, and ex vacuo hydrocephalus.
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TABLE 2. Central Nervous System Clinical Laboratory Results
Test Site Initial Presentation, 2013 Follow-up Evaluation, 2016
RBC CSF 19 cells/mm3 18 cells/mm3
WBC CSF 87 cells/mm3 4 cells/mm3
Neutrophils CSF 11% 0
Lymphocytes CSF 38% 100%
Monocytes CSF 51% 0
Protein CSF 32mg/dl 37mg/dl (40–70)
Glucose CSF 77mg/dl 52mg/dl (15–50)
Lactate CSF 2.0mmol/l (1.2–2.8) 1.96mmol/l (1.0–2.9)
Gram stain CSF Negative Negative
AFB stain CSF Negative
Fungal culture CSF Negative
Bacterial culture CSF Negative Negative
Mycobacterial culture CSF Negative
Borrelia burgdorferi culture CSF Negative
Cytomegalovirus DNA CSF Negative Negative
Enterovirus RNA CSF Negative Negative
HSV-1, 2 DNA CSF Negative Negative
VZV DNA CSF Negative Negative
Neisseria meningitidis DNA CSF Negative
16S rRNA CSF Negative
Enterovirus RNA CSF Negative
HHV-6 DNA CSF Negative
Polyomavirus DNA CSF Negative
Toxoplasma gondii DNA CSF Negative
VZV DNA CSF Negative
EBV quantitation DNA CSF Negative
Parechovirus RNA CSF Negative
Cryptococcal Ag CSF Negative
Giemsa stain Brain Negative
PAS stain Brain Negative
Ziehl–Neelsen stain Brain Negative
Methenamine silver stain Brain Negative
Warthin–Starry stain Brain Negative
Fungal culture Brain Negative
Bacterial culture Brain Negative
Mycobacterial culture Brain Negative
Cytomegalovirus DNA Brain Negative
Bacterial DNA,16S rRNA NAT Brain Negative
Enterovirus RNA Brain Negative
HHV-6 DNA Brain Negative
HSV-1, 2 DNA Brain Negative
Polyomavirus DNA Brain Negative
Toxoplasma gondii DNA Brain Negative
VZV DNA Brain Negative
EBV DNA Brain Negative
Parechovirus RNA Brain Negative
HHV-8 DNA Brain Negative
AFB5 acid-fast bacilli; Ag5 antigen; CSF5 cerebrospinal fluid; EBV5Epstein–Barr virus; HHV5 human herpes virus; HSV5 herpes simplex
virus; 16S rRNA5 16S ribosomal RNA; NAT5 nucleic acid amplification test; PAS5periodic acid–Schiff; RBC5 red blood cell count;
VZV5 varicella zoster virus; WBC5white blood cell count.
protein (translated) level from the control patient and
water samples were subtracted from each patient sample
by matching genus or species level taxonomic identifica-
tions (taxids). Organisms were further investigated if they
were present at >0.2 nonredundant, mapped read pairs
per million read pairs at the species level based on nt
alignment (1 read per 5 million nonredundant reads).
Results
Sequencing Results
A total of 25,069,677 and 13,661,871 paired-end reads
were obtained from the CSF and brain biopsy specimens,
respectively. As described above, the paired-end sequences
were processed through a custom bioinformatics pipeline.
The runtime for the bioinformatics pipeline described
above was 10 to 15 minutes per sample on a single 24-
core server. After filtering, there were 2 genera remaining
in the mNGS dataset from the CSF sample: Bunyam-
wera virus (taxid: 35304) and cucumber green mottle
mosaic virus (taxid: 12234). Only Bunyamwera virus was
considered a credible pathogen. At the species level, the
5 unique pairs of Bunyamwera virus reads mapped to
the CVV nucleoprotein and RNA-dependent RNA poly-
merase with 89 to 100% similarity. Although no
Bunyamwera virus sequences were identified in the nt
results from the brain biopsy sample, the nr output iden-
tified 2 unique read pairs that mapped with 99 to 100%
similarity to the CVV S (small) genome segment that
encodes the nucleocapsid protein and a nonstructural
protein. Thus, the very simple and conservative algo-
rithm described above resulted in a single taxonomic cat-
egory (CVV) in our patient’s CSF sample, which, upon
further investigation, was also present in the brain biopsy
sample. CVV is an orthobunyavirus known to cause
acute neuroinvasive disease but not a chronic meningoen-
cephalitis. CVV sequences have never been previously
detected in this laboratory, nor have CVV reagents or
materials been present in this laboratory. These nonhu-
man sequence reads corresponding to the libraries from
this patient have been deposited at the NCBI Sequence
Read Archive BioProject (PRJNA338853).
Confirmatory Testing
Reverse transcription-PCR (RT-PCR) was performed on
the patient’s brain biopsy tissue and CSF using previously
published CVV primers for the polyprotein gene (ie,
CVV forward [CCAATGCAATTCAGGGCAGT] and
reverse [TGAGTCACCACATGCTGTAAGGT]) accord-
ing to a slightly modified version of a published proto-
col.21 RT-PCR was unsuccessful from CSF, but the
amplicon from the brain biopsy tissue RNA was cloned
into One Shot TOP10 chemically competent Escherichia
coli using the TOPO-TA cloning kit according to the
manufacturer’s protocol (Thermo Fisher Scientific, Wal-
tham, MA). Ampicillin-resistant colonies were Sanger
sequenced (Quintara Biosciences, South San Francisco,
CA). The cloned sequence unambiguously aligned to
CVV (98% similarity); a Basic Local Alignment Search
Tool search of NCBI also returned only CVV hits and
FIGURE 3: Neuropathology. (A) Leptomeningeal thickening and inflammation. (B) Microglial nodule in the cortex. (C) Perivascu-
lar and interstitial lymphocytic infiltrate in the cortex. (D) Perivascular and interstitial lymphocytic infiltrates of predominantly
CD81 T lymphocytes visualized by means of immunolabeling with anti-CD8 antibody.
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did not align to any other viruses. The RNA-dependent
RNA polymerase sequence of the most closely related
Australian orthobunyavirus, Kowanyama virus (GenBank
KC436108.1), had only 80% similarity to the viral poly-
merase sequences obtained from our subject’s sample.22
Virus culture with fresh CSF was attempted on multiple
cell lines (Vero, Vero E6, Aedes albopictus [C6/36], buf-
falo green monkey kidney, human fetal lung [MRC-5],
and rhabdomyosarcoma [RD]) without success. Immuno-
histochemistry was performed on 5 lm sections of
formalin-fixed, paraffin-embedded tissues following previ-
ously described methods with minor modifications,
including a rabbit polyclonal antibody against CVV at
1:100 dilution or normal rabbit IgG incubation for
1 hour, a serum-free protein block incubation (Dako,
Carpinteria, CA), and a polymer-based secondary anti-
body incubation (Thermo Fisher Scientific, Fremont,
CA).23 Ovine fetal central nervous system (CNS) tissue
and skeletal muscle experimentally infected with CVV
and noninfected human brain tissue were included as posi-
tive and negative controls, respectively. The experimentally
infected ovine fetus demonstrated strong intracytoplasmic
immunostaining. No immunostaining was observed in the
noninfected human negative control brain tissue. The sub-
ject’s brain showed intracytoplasmic immunostaining,
primarily seen within glial cells forming glial nodules in
the brain parenchyma (Fig 4).
Discussion
Although viruses are typically associated with acute pre-
sentations of meningoencephalitis, some are known to
cause chronic CNS infection. Immunocompetent patients
have been known to suffer from chronic CNS infections
caused by paramyxoviruses such as measles virus, Nipah
virus, and herpes viruses such as varicella zoster virus,24–26
whereas immunodeficient patients can suffer from chronic
neurologic infections with human immunodeficiency virus
type 1, Epstein–Barr virus, enteroviruses, polyomaviruses,
astroviruses, coronavirus, and even mumps virus.24,27–32
In this report, we expand the spectrum of viral
causes of chronic meningoencephalitis in the setting of
immunodeficiency to include the orthobunyavirus CVV,
a mosquito-borne orthobunyavirus first identified in
Cache Valley, Utah in 1956.4 Orthobunyaviruses are seg-
mented negative-stranded RNA viruses whose genomes
are composed of large, medium, and small segments.
Other viruses in the orthobunyavirus family of public
health importance include California encephalitis virus,
Jamestown Canyon virus, and LaCrosse virus.33,34 CVV
FIGURE 4: Immunohistochemistry. (A) Strong intracytoplasmic immunostaining in ovine fetal brain using anti–Cache Valley virus
(CVV) polyclonal antibody (Ab) and stained with brown 3,30-diaminobenzidine chromogen (positive control). (B) No immunos-
taining in noninfected human brain using anti-CVV polyclonal Ab (negative control). (C, D) Intracytoplasmic immunostaining in
subject’s brain using anti-CVV polyclonal Ab. Scale bar520mm (A–C) and 13mm (D).
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has rarely been reported to cause neuroinvasive disease in
immunocompetent patients, with clinical presentations
ranging from a self-limited aseptic meningitis to a fatal
meningoencephalitis with multiorgan failure.5–7 CVV has
not previously been reported to cause a chronic infection
in humans.
Although there are no approved antiviral agents
known to treat CVV, the identification of the virus did
reinforce a switch from obtaining IVIg pooled from Aus-
tralian donors to IVIg pooled from donors in the United
States, given the possibility that the latter IVIg donor
pool might contain neutralizing antibodies against
CVV.35–37 Unfortunately, this change in treatment strat-
egy did not arrest the patient’s relentless neurologic
decline. His ataxia progressed until he could no longer
walk; he ceased communicating verbally and eventually
stopped eating and drifted into a coma. He was placed
in hospice care and died in early 2017, 42 months after
his initial presentation. After his death, his parents
reported that they derived great comfort knowing the
underlying cause of their son’s illness. Our patient’s case
highlights the need to make specific microbiological diag-
noses both so that targeted therapies can be developed
and also to provide clarity to patients and families.
Whereas CVV is widespread throughout North and
South America, it and other members of the Bunyamwera
serogroup have not been previously detected in Australia.22
Given that CVV is a mosquito-borne virus that can be car-
ried by at least 33 species of mosquitoes across 7 genera,
there are likely mosquito species competent to transmit
CVV in Australia.38,39 Although we have no evidence that
wider transmission has occurred, it is plausible that our sub-
ject could have transmitted CVV to mosquitos in Australia
during the 3-year period since his return from the United
States. The possibility of having introduced a mosquito-
borne virus to a new locale is made even more salient by the
recent international Zika virus crisis. The spread of Zika to
Latin America was in part exacerbated by the delayed recog-
nition of its introduction to Brazil. Recent phylogenetic
studies have indicated that Zika virus was circulating for 18
months before it was identified as a pathogen, and for 24
months before it was determined that Zika was likely respon-
sible for the recent increase in the incidence of microceph-
aly.40 The most dramatic example of a virus spreading
undetected among human populations over many decades
remains HIV-1.41
Because CVV is rarely identified as a cause of
human disease and has not been reported in Australia pre-
viously, there are no traditional candidate-based diagnostic
tests for this virus available in Australia. This unusual case
highlights the ability for mNGS to identify pathogens not
previously associated with a clinical phenotype and not
known to circulate in a geographic area.2,3 It is also
important to note that mNGS was able to identify CVV
in the CSF of this patient; if these results had been avail-
able before the brain biopsy, they could have obviated the
need for this invasive procedure. The ability to identify
unanticipated infections in CSF via mNGS in this patient
and others motivates the ongoing prospective, multicenter
study currently underway to determine the performance
characteristics of an mNGS CSF assay performed in a
clinical laboratory environment for patients with acute
meningitis with or without encephalitis (http://www.
ciapm.org/project/precision-diagnosis-acute-infectious-diseases).
When applied more broadly to global pathogen surveil-
lance efforts, mNGS will significantly enhance the detec-
tion and monitoring of global biothreats. Finally, this
case extends the spectrum of viruses known to cause
chronic meningoencephalitis.
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